News Two Expensive Diabetic Macular Edema Drugs Not Cost-effective by Medscape • 2016/06/09 • 0 Comments Anti-VEGF medicines aflibercept and ranibizumab would have to drop in price by 69% and 80%, respectively, to be worth the societal cost compared with bevacizumab, a new study has found. Medscape Medical News Full Story →